Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Dimebon, Grasping at Straws

    Robert Langreth, an editor at Forbes, points to a possible way that Dimebon could get approval for Alzheimer’s: for its behavioral effects, not anything to do with amyloid or memory. I’m not buying it, I have to say. Even Langreth’s source admits that behavioral numbers didn’t reach statistical significance. I don’t se… Read More
  • Alzheimer's Disease

    Dimebon Comes Crashing to Earth

    Earlier this month I wrote about Medivation and their Russian-derived clinical candidate for Alzheimer’s disease, Dimebon (latrepirdine). At the time, I wrote that “A lot of eye-catching numbers from small Phase II trials tend to flatten out in the wider world of Phase III, and if forced, that’s the way I’d bet here.”… Read More
  • Alzheimer's Disease

    A Modest Literature Proposal

    Looking through the latest papers to show up in the Journal of Medicinal Chemistry, this one on BACE-1 inhibitor compounds caught my eye. Perhaps I’m about to be unfair to it. At any rate, I’m going to ask of it something it doesn’t provide: data in something that’s alive. Doesn’t have to be a person… Read More
  • Alzheimer's Disease

    Dimebon for Alzheimer’s: A Black Box Indeed

    Dimebon (dimebolin) is a perfect example of the black-box nature of drug research for the central nervous system. Any medicinal chemist who looks at its structure would immediately say “CNS”, but shrug when asked what specific receptors it might hit. I’d have guessed histamine (correctly), since loratidine used to pay my salary, a… Read More
  • Alzheimer's Disease

    Two Doses of Crazy

    I’d like to take the time this morning to deal with two conspiracy theorists, and I’ll take them in order of increasing foil-hat thickness. First up is Joe Collier, an emeritus professor who writes a blog for the British Medical Journal. He notes the recent study that suggested that cell phone emissions could have a… Read More
  • Alzheimer's Disease

    An Alzheimer’s Compound Runs Into Big Trouble

    Another interesting approach to Alzheimer’s therapy has just taken a severe jolt in the clinic. Elan and Transition Therapeutics were investigating ELEND005, also known as AZD-103, which was targeted at breaking down amyloid fibrils and allowing the protein to be cleared from the brain. Unfortunately, the two highest-dose patient groups exper… Read More
  • Academia (vs. Industry)

    Short Topics From All Over

    (1) Bnet Pharma on “How Not to Write a Pharma Press Release“. Privately held Epeius is sending out bulletins loaded with phrases like “more stunning results” and “Epeius Biotechnologies draws the sword of targeted gene delivery from the stone of chemistry and physics”. If they were publicly traded, this would be… Read More
  • Alzheimer's Disease

    Amyloid in Trouble

    Here’s an interesting look at the current state of the Alzheimer’s field from Bloomberg. The current big hope is Wyeth (and Elan)’s bapineuzumab, which I last wrote about here. That was after the companies reported what had to be considered less-than-hoped-for efficacy in the clinic. The current trial is the one sorted out by APOE… Read More
  • Alzheimer's Disease

    Does Glucophage Make Alzheimer’s Worse?

    Metformin, now there’s a drug story for you. It’s a startlingly small molecule, the sort of thing that chemists look and and say “That’s a real drug?” It kicked around in the literature and the labs in the 1960s, was marketed in Europe in the 1980s but was shopped around in the US for quite… Read More
  • Alzheimer's Disease

    Short Items: India, Sanjay Gupta, Satori Pharmaceuticals

    I have a few short links for everyone today. One series of posts that you might not have seen from Xconomy is a tour of the technological hot spots of India by Boston University’s Vinit Nijhawan. It’s interesting stuff for people like me who haven’t been to the country, and he isn’t shy about pointing… Read More
...101112...